GlassScriptPhysician profile
Vicki A Blackmon-Davis
NPI 1861403313
$1,417.73
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $388 · 2021: $426 · 2022: $276 · 2023: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $174.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.57 | 2019-2023 | Jardiance, Synjardy |
| Kowa Pharmaceuticals America, INC. | $264.50 | 2019-2022 | |
| Pfizer INC. | $100.72 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $71.52 | 2019-2022 | |
| Glaxosmithkline, LLC. | $61.62 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $60.50 | 2019-2021 | |
| Lilly USA, LLC | $56.20 | 2019-2021 | |
| Allergan, INC. | $48.25 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $47.74 | 2023 | Quviviq |
| Abbvie INC. | $38.83 | 2020-2023 | Ubrelvy |
| Abbott Laboratories | $37.39 | 2022-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $32.72 | 2020-2022 | |
| Althera Pharmaceuticals LLC | $28.60 | 2021-2022 | |
| Ibsa Pharma INC. | $24.93 | 2021-2022 | |
| Assertio Therapeutics, INC. | $20.54 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $19.97 | 2021 | |
| Novo Nordisk INC | $19.21 | 2023 | Rybelsus |
| Amgen INC. | $19.15 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.09 | 2022 | |
| Astellas Pharma US INC | $16.37 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.39 | 2023 | |
| Amarin Pharma, INC. | $14.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Blackmon-Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.